Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia | Biomarker Research | Full Text

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia | Biomarker Research | Full Text

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for induction therapy of AML. When used in ...

Authors:Bo Yu and Delong Liu

Citation:Biomarker Research 2019 7:24

Content type:Review

Published on: 31 October 2019

• ViewFull Text
 
• ViewPDF